速递|手握9个GLP-1项目,全球第三大多肽CRDMO即将上市港交所

GLP1减重宝典
04 Jun

整理 | GLP1减重宝典内容团队2025年6月3日,泰德医药(浙江)股份有限公司(Medtide Inc.)顺利通过港交所聆讯,迈出上市关键一步。作为全球第三大专注于多肽的CRDMO(合同研究、开发与生产)企业,泰德医药正借助GLP-1类药物的热潮,寻求在资本市场的新突破。全球多肽CRDMO格局:泰德医药位列第三,市场份额1.5%根据弗若斯特沙利文的数据,按2023年销售收入计,泰德医药在全球...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10